Catalyst Biosciences, Inc Earning Date (CBIO)

USA |NASDAQ |USD

CBIO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.64
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $1.13M

Catalyst Biosciences, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

CBIO Earnings Date & History Chart

CBIO Earnings & Revenue Forecast

CBIO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $-1.35 $-1.71 $-1.14

CBIO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-1.35 $-2.10 $-2.10

CBIO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 3 $5.00M $0.00 $10.00M

CBIO Earnings Date & Revenue History

CBIO Earnings History

|
Show More
Show More

CBIO Revenue History

|
Show More
Show More

Catalyst Biosciences, Inc Next Earnings Date & Report

CBIO Next Earnings Date & Report Preview: Jun 2022 (FQ)

CBIO's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Catalyst Biosciences, Inc Previous Earnings Dates & Reports

CBIO Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Catalyst Biosciences, Inc's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.

CBIO Previous Earnings Date & Report Recap: Dec 2020 (FY)

Catalyst Biosciences, Inc's previous annual earnings date was Mar 4, 2021 for its fiscal year ended Dec 31, 2020.

CBIO's earnings per share (EPS) was $-2.85, missing the consensus analysts forecast of $-2.70 by 5.56% , and higher than the previous year's EPS (Dec 2019) by -38.04%.

Revenues were $20.95M.

The company reported a net income of $-56.24M.

Catalyst Biosciences, Inc reported a free cash flow of $-55.31M for its fiscal year, compared to $-43.68M a year ago.

The company ended the fiscal year with $1.64M in total debt, a decrease of -8.77% compared to the previous year.